Firbas C - Search Results

1

Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor.

Hobl EL, Derhaschnig U, Firbas C, Schoergenhofer C, Schwameis M, Jilma B. Hobl EL, et al. Among authors: firbas c. Eur J Clin Invest. 2013 Dec;43(12):1258-61. doi: 10.1111/eci.12168. Epub 2013 Sep 23. Eur J Clin Invest. 2013. PMID: 24112116

2

The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia.

Spiel AO, Firbas C, Mayr FB, Leitner JM, Schmidt B, Knöbl P, Varadi K, Jilma B. Spiel AO, et al. Among authors: firbas c. Thromb Haemost. 2005 Dec;94(6):1148-55. doi: 10.1160/TH05-01-0059. Thromb Haemost. 2005. PMID: 16411386 Clinical Trial.

3

Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia.

Leitner JM, Firbas C, Mayr FB, Reiter RA, Steinlechner B, Jilma B. Leitner JM, et al. Among authors: firbas c. Clin Pharmacol Ther. 2006 Jan;79(1):23-34. doi: 10.1016/j.clpt.2005.10.003. Clin Pharmacol Ther. 2006. PMID: 16413239 Clinical Trial.

4

Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans.

Spiel AO, Mayr FB, Firbas C, Quehenberger P, Jilma B. Spiel AO, et al. Among authors: firbas c. J Thromb Haemost. 2006 Feb;4(2):411-6. doi: 10.1111/j.1538-7836.2006.01715.x. J Thromb Haemost. 2006. PMID: 16420574 Free article. Clinical Trial.

5

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS. Firbas C, et al. Vaccine. 2006 May 15;24(20):4343-53. doi: 10.1016/j.vaccine.2006.03.009. Epub 2006 Mar 20. Vaccine. 2006. PMID: 16581161 Clinical Trial.

6

Ethnic differences in plasma levels of interleukin-8 (IL-8) and granulocyte colony stimulating factor (G-CSF).

Mayr FB, Spiel AO, Leitner JM, Firbas C, Kliegel T, Jilma B. Mayr FB, et al. Among authors: firbas c. Transl Res. 2007 Jan;149(1):10-4. doi: 10.1016/j.trsl.2006.06.003. Transl Res. 2007. PMID: 17196517

7

Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia.

Leitner JM, Mayr FB, Firbas C, Spiel AO, Steinlechner B, Novellini R, Jilma B. Leitner JM, et al. Among authors: firbas c. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):25-36. doi: 10.1177/039463200702000104. Int J Immunopathol Pharmacol. 2007. PMID: 17346425 Free article. Clinical Trial.

8

Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation.

Leitner JM, Jilma B, Mayr FB, Cardona F, Spiel AO, Firbas C, Rathgen K, Stähle H, Schühly U, Graefe-Mody EU. Leitner JM, et al. Among authors: firbas c. Clin Pharmacol Ther. 2007 Jun;81(6):858-66. doi: 10.1038/sj.clpt.6100153. Epub 2007 Apr 4. Clin Pharmacol Ther. 2007. PMID: 17410124 Free article. Clinical Trial.

9

Effects of low dose endotoxemia on endothelial progenitor cells in humans.

Mayr FB, Spiel AO, Leitner JM, Firbas C, Sieghart W, Jilma B. Mayr FB, et al. Among authors: firbas c. Atherosclerosis. 2007 Nov;195(1):e202-6. doi: 10.1016/j.atherosclerosis.2007.04.003. Epub 2007 May 9. Atherosclerosis. 2007. PMID: 17490672 Clinical Trial.

10

Duffy antigen modifies the chemokine response in human endotoxemia.

Mayr FB, Spiel AO, Leitner JM, Firbas C, Kliegel T, Jilma-Stohlawetz P, Derendorf H, Jilma B. Mayr FB, et al. Among authors: firbas c. Crit Care Med. 2008 Jan;36(1):159-65. doi: 10.1097/01.CCM.0000297875.55969.DB. Crit Care Med. 2008. PMID: 18007272 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page